Highlights Adhera Therapeutics, Inc.

Equities

ATRX

US00687E4061

Market Closed - OTC Markets Other stock markets 10:26:15 2024-05-20 am EDT			5-day change	1st Jan Change
0.0045 ^USD	-25.00%		0.00%	-85.00%

Jan. 18	Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	CI
Jan. 16	Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	Jan. 18	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Adhera Therapeutics, Inc. announced that it has received $0.364285 million in funding	23-02-15	CI
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes	23-01-25	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Reverse Split: 1 of 20	22-10-05	FA
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Adhera Therapeutics, Inc. enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group.	22-07-18	CI
Adhera Therapeutics, Inc. Planning to Initiate A Phase 2 Clinical Trial of Mlr-1023 as new Treatment for Type 1 Diabetes	22-05-19	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-22	CI
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds Nash and Pulmonary Inflammation to Portfolio of Target Indications	21-10-20	CI
Manufacturing Commences on Adhera Therapeutics, Inc.’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease	21-10-15	CI
Adhera Therapeutics, Inc. Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs	21-09-13	CI
Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate	21-08-24	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Adhera Therapeutics, Inc.

Equities

ATRX

US00687E4061

Highlights

Filters